When these medications are administered to a patient receiving glipizide extended-release tablets, monitor the patient closely for hypoglycemia. 2007 Sep;29(9):1900-14. doi: 10.1016/j.clinthera.2007.09.011.Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.Clin Ther. In the glipizide extended-release tablets, the medication is contained within a non-dissolvable shell that has been specially designed to slowly release the drug so the body can absorb it.Trademarks are the property of their respective owners.3.1 Carcinogenesis, Mutagenesis, Impairment of FertilityA twenty month study in rats and an eighteen month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. If you have signs or symptoms of low blood sugar, eat or drink something with sugar in it right away. What Are Some Side Effects That I Need to Call My Doctor About Right away? Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.Glipizide extended-release tablets are supplied as 2.5 mg, 5 mg, and 10 mg round, biconvex tablets and imprinted with black ink as follows:Recommended Storage: The tablets should be protected from moisture and humidity. Dose adjustments during pregnancy and the postpartum period Avoid use of glipizide extended-release tablets in patients with G6PD deficiency. The postprandial insulin and C-peptide responses continue to be enhanced after at least 6 months of treatment. Hypoglycemia is also more likely to occur when caloric intake is deficient, after severe or prolonged exercise, or when alcohol is ingested.The patient’s ability to concentrate and react may be impaired as a result of hypoglycemia. Concomitant treatment with fluconazole increases plasma concentrations of glipizide, which may lead to hypoglycemia [see Clinical Pharmacology (12.3)].Glipizide extended-release tablets should be administered at least 4 hours prior to the administration of colesevelam. 2.2 Use with Other Glucose Lowering Agents. In a single dose study in 24 healthy subjects, four 5-mg, two 10-mg, and one 20-mg glipizide extended-release tablets were bioequivalent. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by Known hypersensitivity to glipizide or any of the product’s ingredients. However, since glipizide is highly protein bound and hepatic biotransformation is the predominant route of elimination, the pharmacokinetics and/or pharmacodynamics of glipizide may be altered in patients with hepatic impairment. When these medications are discontinued from patients receiving glipizide extended-release tablets, monitor the patients closely for hypoglycemia.Alcohol, beta-blockers, clonidine, and reserpine may lead to either potentiation or weakening of the glucose-lowering effect. Name must be less than 100 characters Avoid use of glipizide extended-release tablets in patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic).The following serious adverse reactions are discussed in more detail below and elsewhere in the labeling:Hypoglycemia [see Warnings and Precautions (5.1)] : 1-877-993-8779.What are the ingredients in glipizide extended-release tablets?Inactive ingredients: acetyltributyl citrate, colloidal silicon dioxide, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, methacrylic acid copolymer and polyethylene glycol. Glipizide extended-release tablets may cause low blood sugar. Copy the URL below and paste it into your RSS Reader application.DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use.